AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626

Reuters

03/19

AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626

AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.
PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.
The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.
The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.
Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2620410102"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620410102\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620410102?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620410102","market":"fut","top_or_hot":-1,"title":"AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        </li>\n<li>\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        </li>\n<li>\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        </li>\n<li>\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        </li>\n<li>\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        </li>\n<li>\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        </li>\n<li>\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        </li>\n<li>\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        </li>\n<li>\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2V16.EUR","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1L9bvR:1","article_id":"2620410102","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620410102","pubTimestamp":1773918035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.The first-in-human Phase 1 trial  is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4112":"金融交易所和数据","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","ACIU":"AC Immune SA","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC"},"translate_title":"AC Immune报告TDP-43 PET示踪剂ACI-19626的1期体内脑成像数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ACIU":0.9},"content_text":"AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    \n\n\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        \n\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        \n\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        \n\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        \n\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}